The application of DNA repair vectors to gene therapy

Current Opinion in Biotechnology

Volumn 13, Issue 5, 2002, Pages 473-481

  Kren, Betsy T ^a   Steer, Clifford J ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DNA FRAGMENT; GENOMIC DNA; SINGLE STRANDED DNA;

CHIMERAPLASTY; CHROMOSOME MUTATION; DNA REPAIR; DNA SEQUENCE; DNA VECTOR; GENE CONTROL; GENE REPLACEMENT THERAPY; GENE TARGETING; GENE THERAPY; GENETIC DISORDER; GENOME; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0036811533     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(02)00370-1     Document Type: Review

References (71)

1. Müller K., Heller H., Doerfler W. Foreign DNA integration. Genome wide perturbations of methylation and transcription in the recipient genomes. J Biol Chem. 276:2001;14271-14278. Even nonrandom integration may have deleterious effects on the host genome.
2. Baylin S.B., Esteller M., Rountree M.R., Bachman K.E., Schuebel K., Herman J.G. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet. 10:2001;687-692.
3. Yáñez R.J., Porter A.C.G. Therapeutic gene targeting. Gene Ther. 5:1998;149-159.
4. Vasquez K.M., Marburger K., Intody Z., Wilson J.H. Manipulating the mammalian genome by homologous recombination. Proc Natl Acad Sci USA. 98:2001;8403-8410. A nice review of homologous recombination, including TFOs.
5. Kotani H., Kmiec E.B. A role for RNA synthesis in homologous pairing events. Mol Cell Biol. 14:1994;6097-6106.
6. Kmiec E.B., Kren B.T., Steer C.J. Targeted gene repair in mammalian cells using chimeric RNA/DNA oligonucleotides. Friedman T. Development of Human Gene Therapy. 1999;643-670 Cold Spring Harbor Laboratory Press.
7. Gamper H.B. Jr, Cole-Strauss A., Metz R., Parekh H., Kumar R., Kmiec E.B. A plausible mechanism for gene correction by chimeric oligonucleotides. Biochemistry. 39:2000;5808-5816. Outstanding biochemical dissection of the putative mechanisms and factors required for chimeraplasty.
8. Cole-Strauss A., Yoon K., Xiang Y., Byrne B.C., Rice M.C., Gryn J., Holloman W.K., Kmiec E.B. Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide. Science. 273:1996;1386-1389.
9. Kren B.T., Bandyopadhyay P., Steer C.J. In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides. Nat Med. 4:1998;285-290.
10. Kren B.T., Parashar B., Bandyopadhyay P., Chowdhury N.R., Chowdhury J.R., Steer C.J. Correction of the UDP-glucuronosyltransferase gene defect in the Gunn rat model of Crigler-Najjar syndrome type I with a chimeric oligonucleotide. Proc Natl Acad Sci USA. 96:1999;10349-10354. Demonstration that chimeraplast treatment in vivo in an accurate animal model of a human disease can provide sufficient genomic modification for therapeutic benefit.
11. Bandyopadhyay P., Ma X., Linehan-Stieers C., Kren B.T., Steer C.J. Nucleotide exchange in genomic DNA of rat hepatocytes using RNA/DNA oligonucleotides. Targeted delivery of liposomes and polyethyleneimine to the asialoglycoprotein receptor. J Biol Chem. 274:1999;10163-10172.
12. Steer C.J., Kren B.T., Roy Chowdhury N., Roy Chowdhury J. Liver-directed gene therapy. Arias I.M., Boyer J.L., Chisari F.V., Fausto N., Schachter D., Shafritz D.A. The Liver: Biology and Pathobiology. 4th edn :2001;941-962 Lippincott Williams & Wilkins.
13. 1-antitrypsin deficiency. Chest. 1221:2002;91S-97S. This report suggests that the structure/function relationships and factors/pathways involved in chimeraplasty are conserved between bacteria and mammals.
14. Lui L., Rice M.C., Kmiec E.B. In vivo gene repair of point and frameshift mutations directed by chimeric RNA/DNA oligonucleotides and modified single-stranded oligonucleotides. Nucleic Acids Res. 29:2001;4238-4250.
15. Rice M.C., Bruner M., Czymmek K., Kmiec E.B. In vitro and in vivo nucleotide exchange directed by chimeric RNA/DNA oligonucleotides in Saccharomyces cerevisae. Mol Microbiol. 40:2001;857-868. This study identifies some of the factors involved in chimeraplasty, including ones that suppress conversion.
16. Alexeev V., Igoucheva O., Domashenko A., Cotsarelis G., Yoon K. Localized in vivo genotypic and phenotypic correction of the albino mutation in skin by RNA-DNA oligonucleotide. Nat Biotechnol. 18:2000;43-47. The second demonstration that in vivo correction of a single point-mutation led to a phenotypic alteration.
17. Lai L.-W., Lein Y.-H.H. Homologous recombination based gene therapy. Exp Nephrol. 7:1999;11-14.
18. Lai L, Doty D, Khan R, Omera M, Lien Y-H: Conversion of a single base pair mutation in newborn carbonic anhydrase (CA) II deficient mice by chimeric RNA/DNA oligonucleotides. Mol Therapy 2001, S295. Chimeraplasty can repair multiple tissue types in vivo. Moreover, it demonstrates that the route of administration profoundly influences efficiency.
19. Bertoni C., Rando T.A. Dystrophin gene repair in mdx muscle precursor cells in vitro and in vivo mediated by RNA-DNA chimeric oligonucleotides. Hum Gene Ther. 13:2002;707-718. Thought provoking ex vivo gene therapy approach for muscular dystrophy.
20. Rando T.A., Disatnik M.H., Zhou L.Z. Rescue of dystrophin expression in mdx mouse muscle by RNA/DNA oligonucleotides. Proc Natl Acad Sci USA. 97:2000;5363-5368.
21. Bartlett R.J., Stockinger S., Denis M.M., Bartlett W.T., Inverardi L., Le T.T., thi Man N., Morris G.E., Bogan D.J., Metcalf-Bogan J., et al. In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide. Nat Biotechnol. 18:2000;615-622. Gene repair by chimeraplasty works in a large animal model of muscular dystrophy.
22. Beetham P.R., Kipp R.B., Sawycky X.L., Arntzen C.J., May G.D. A tool for functional plant genomics: Chimeric RNA/DNA oligonucleotides cause in vivo gene-specific mutations. Proc Natl Acad Sci USA. 96:1999;8774-8778.
23. Zhu T., Peterson D.J., Tagliani L., St Claire G., Baszczynski C.L., Bowen B. Targeted manipulation of maize genes in vivo using chimeric RNA/DNA oligonucleotides. Proc Natl Acad Sci USA. 96:1999;8768-8773.
24. Li Z.-H., Liu D.-P., Yin W.-X., Guo Z.-C., Liang C.-C. Targeted correction of the β-thalassemia and targeted mutagenesis of the nucleotide associated with HPFH by RNA/DNA oligonucleotides: potential for β-thalassemia gene therapy. Blood Cells Mol Dis. 27:2001;530-538.
25. - cells. Gene Ther. 9:2002;118-126. This study suggests that ex vivo gene therapy using chimeraplasts may be feasible for certain hemoglobinopathies.
26. Tagalakis A.D., Graham I.R., Riddell D.R., Dickson J.G., Owen J.S. Gene correction of the apolipoprotein (apo) E2 phenotype to wild-type apoE3 by in situ chimeraplasty. J Biol Chem. 276:2001;13226-13230. Confirmation that high-efficieny gene repair using chimeraplasts can be achieved both in vitro and in vivo.
27. Graham I.R., Manzano A., Tagalakis A.D., Sperber G., Hill V., Beattie S., Schepelmann S., Dickson G., Owen J.S. Gene repair validation. Nat Biotechnol. 19:2001;507-508. Excellent discussion of the variability and complexities associated with targeted gene repair using chimeraplasts.
28. Bertoni C., Lau C., Rando T.A. Chimeraplast-mediated exon skipping as an approach to gene therapy for frame-shift deletions of the dystrophin gene. Mol Ther. 5:2002;S361. A novel approach using chimeraplasty and possible strategy for deleting deleterious coding sequences, such as the expanded repeats associated with neurodegenerative disorders.
29. Lai L.-W., Whitehair O., Campbell P.D., Lein Y.-H.H. Effect of ultraviolet B radiation on chimeric RNA-DNA oligonucleotide induced gene correction. Mol Ther. 5:2002;S346. Increasing DNA repair activity can improve chimeraplast-mediated gene conversion.
30. Chen Z., Felsheim R., Wong P., Augustin L.B., Metz R., Kren B.T., Steer C.J. Mitochondria isolated from liver contain the essential factors required for RNA/DNA oligonucleotide-targeted gene repair. Biochem Biophys Res Commun. 285:2001;188-194. This article suggests the potential to modify the mitochondrial genome using chimeraplasts.
31. Thorpe P.H., Stevenson B.J., Porteous D.J. Functional correction of episomal mutations with short DNA fragments and RNA - DNA oligonucleotides. J Gene Med. 4:2002;195-204.
32. van der Steege G., Schuilenga-Hut P.H., Buys C.H., Scheffer H., Pas H.H., Jonkman M.F. Persistent failures in gene repair. Nat Biotechnol. 19:2001;305-306.
33. Parekh-Olmedo H., Kranic D., Kmiec E.B. Targeted gene repair and its application to neurodegenerative disorders. Neuron. 33:2002;495-498.
34. Rice M.C., Czymmek K., Kmiec E.B. The potential of nucleic acid repair in functional genomics. Nat Biotechnol. 19:2001;321-326.
35. Parekh-Olmedo H., Czymmek K., Kmiec E.B. Targeted gene repair in mammalian cells using chimeric RNA/DNA oligonucleotides and modified single-stranded vectors. Sci STKE. 73:2001;PL1-12. A well-written technical article on using chimeraplasts and SSONs.
36. Santana E., Peritz A.E., Iyer S., Uitto J., Yoon K. Different frequency of gene targeting events by the RNA-DNA oligonucleotide among epithelial cells. J Invest Dermatol. 111:1998;1172-1177.
37. Gamper H.B., Parekh H., Rice M.C., Bruner M., Youkey H., Kmiec E.B. The DNA strand of chimeric RNA/DNA oligonucleotides can direct gene repair/conversion activity in mammalian and plant cell-free extracts. Nucleic Acids Res. 28:2000;4332-4339. Seminal article demonstrating that site-directed alteration of DNA can be achieved with SSONs.
38. Lui L., Cheng S., van Brabant A.J., Kmiec E.B. Rad51p and Rad54p, but not Rad52p, elevate gene repair in Saccharomyces cerevisiae directed by modified single-stranded oligonucleotide vectors. Nucleic Acids Res. 30:2002;2742-2750. An excellent study defining various factors that may be involved in mediating SSON genomic alteration.
39. Igoucheva O., Alexeev V., Yoon K. Targeted gene correction by small single-stranded oligonucleotides in mammalian cells. Gene Ther. 8:2001;391-399. A detailed comparison of targeted gene repair using SSONs with cell-free extracts, together with episomal and chromosomal reporter genes in cultured cells.
40. Lui L., Rice M.C., Dury M., Cheng S., Gamper H., Kmiec E.B. Strand bias in targeted gene repair is influenced by transcriptional activity. Mol Cell Biol. 22:2002;3852-3863. An important and thought-provoking article that underscores the importance of understanding the mechanisms and factors involved in DNA repair.
41. Yamamoto T., Moerschell R.P., Wakem L.P., Komar-Panicucci S., Sherman F. Strand-specificity in the transformation of yeast with synthetic oligonucleotides. Genetics. 131:1992;811-819. A seminal paper on gene alteration using SSONs in vivo. A reminder that most 'new technology' is simply an improvement of previously described strategies.
42. Fujioka K.-i, Aratani Y., Kusano K., Koyama H. Targeted recombination with single-stranded DNA vectors in mammalian cells. Nucleic Acids Res. 3:1993;407-412.
43. Hunger-Bertling K., Harrer P., Bertling W. Short DNA fragments induce site specific recombination in mammalian cells. Mol Cell Biochem. 92:1990;107-116.
44. Goncz K.K., Gruenert D.C. Site-directed alteration of genomic DNA by small-fragment homologous replacement. Methods Mol Biol. 133:1999;85-99. An excellent how-to-do methods article on small fragment homologous replacement.
45. Colosimo A., Goncz K.K., Novelli G., Dallapiccola B., Gruenert D.C. Targeted correction of a defective selectable marker gene in human epithelial cells by small DNA fragments. Mol Ther. 3:2001;178-185.
46. Kunzelmann K., Legendre J.Y., Knoell D.L., Escobar L.C., Xu Z., Gruenert D.C. Gene targeting of CFTR DNA in CF epithelial cells. Gene Ther. 3:1996;859-867.
47. Goncz K.K., Kunzelmann K., Xu Z., Gruenert D.C. Targeted replacement of normal and mutant CFTR sequences in human airway epithelial cells using DNA fragments. Hum Mol Genet. 7:1998;1913-1919.
48. Bruscia E., Sangiuolo F., Sinibaldi P., Goncz K.K., Gruenert D.C. Isolation of cell lines corrected at ΔF508-CFTR locus by SFHR-mediated targeting. Gene Ther. 9:2002;683-685. The latest report from the group that has advanced SFHR as an effective method of gene conversion for the three-base pair ΔF508 CFTR mutation.
49. Goncz K.K., Prokopishyn N.L., Chow B.L., Davis B.R., Gruenert D.C. Application of SFHR to gene therapy of monogenic disorders. Gene Ther. 9:2002;691-694. Reinforces the notion that nuclear delivery of the molecules is essential for gene conversion. Would cells that are refractory to SFHR be amenable to chimeraplasty for gene correction, or vice versa?
50. Kapsa R., Quigley A., Lynch G.S., Steeper K., Kornberg A.J., Gregorevic P., Austin L., Byrne E. In vivo and in vitro correction of the mdx dystrophin gene nonsense mutation by short-fragment homologous replacement. Hum Gene Ther. 12:2001;629-642. This report indicates that SFHR can correct the mdx mutation at the genomic level, both in vitro and in vivo.
51. Goncz K.K., Colosimo A., Dallapiccola B., Gagne L., Hong K., Novelli G., Papahadjopoulos D., Sawa T., Schreier H., Wiener-Kronish J., et al. Expression of ΔF508 CFTR in normal mouse lung after site-specific modification of CFTR sequences by SFHR. Gene Ther. 8:2001;961-965. The first in vivo generation of a three-base pair deletion in lung. This proof-of-principle article underscores the difficulty of transferring work from cell culture to animals and the importance of delivery.
52. Hirata R.K., Russell D.W. Design and packaging of adeno associated virus gene targeting vectors. J Virol. 74:2000;4612-4620. An excellent article describing the technical aspects of an approach to use viral vectors for gene augmentation and/or gene repair.
53. Inoue N., Dong R., Hirata R.K., Russell D.W. Introduction of single base substitutions at homologous chromosomal sequences by adeno-associated virus vectors. Mol Ther. 3:2001;526-530.
54. Inoue N., Hirata R.K., Russell D.W. High-fidelity correction of mutations at multiple chromosomal positions by adeno-associated virus vectors. J Virol. 73:1999;7376-7380. A novel approach showing that a viral vector could be effective at both gene augmentation as well as gene repair.
55. Knauert M.P., Glazer P.M. Triplex forming oligonucleotides: sequence specific tools for gene targeting. Hum Mol Genet. 10:2001;2243-2251. An outstanding review of the triplex-forming oligonucleotide field and the strategies exploiting their ability to induce endogenous DNA alteration pathways.
56. Amosova O.A., Fresco J.R. A search for base analogs to enhance third-strand binding to 'inverted' target base pairs of triplexes in the pyrimidine/parallel motif. Nucleic Acids Res. 27:1999;4632-4635.
57. Vasquez K.M., Dagel J.M., Weeks D.L., Glazer P.M. Chromosome targeting at short polypurine sites by cationic triplex-forming oligonucleotides. J Biol Chem. 276:2001;38536-38541.
58. Vasquez K.M., Wang G., Havre P.A., Glazer P.M. Chromosomal mutations induced by triplex-forming oligonucleotides in mammalian cells. Nucleic Acids Res. 27:1999;1176-1181.
59. Chan P.P., Lin M., Faruqi A.F., Powell J., Seidman M.M., Glazer P.M. Targeted correction of an episomal gene in mammalian cells by a short DNA fragment tethered to a triplex-forming oligonucleotide. J Biol Chem. 274:1999;11541-11548. One of the first reports on the use of this strategy for site-specific genomic alteration.
60. Culver K.W., Hsieh W.-T., Huyen Y., Chen V., Liu J., Khripine Y., Khorlin A. Correction of chromosomal point mutations in human cells with bifunctional oligonucleotides. Nat Biotechnol. 17:1999;989-993. A bifunctional TFO can induce genomic modification at a level sufficient to have potential therapeutic application.
61. Datta H.J., Chan P.P., Vasquez K.M., Gupta R.C., Glazer P.M. Triplex-induced recombination in human cell-free extracts. Dependence on XPA and HsRad51. J Biol Chem. 276:2001;18018-18023.
62. Vasquez K.M., Christensen J., Li L., Finch R.A., Glazer P.M. Human XPA and RPA DNA repair proteins participate in specific recognition of triplex-induced helical distortions. Proc Natl Acad Sci USA. 99:2002;5848-5853.
63. Luo Z., Macris M.A., Faruqi A.F., Glazer P.M. High-frequency intrachromosomal gene conversion induced by triplex-forming oligonucleotides microinjected into mouse cells. Proc Natl Acad Sci USA. 97:2000;9003-9008. This report suggests that harnessing the endogenous HR activity induced by TFOs has potential as a useful tool to modify the genome.
64. Vasquez K.M., Narayanan L., Glazer P.M. Specific mutations induced by triplex-forming oligonucleotides in mice. Science. 290:2000;530-533.
65. Datta H.J., Glazer P.M. Intracellular generation of single-stranded DNA for chromosomal triplex formation and induced recombination. Nucleic Acids Res. 29:2001;5140-5147. This vector system has the potential to generate in vivo single-stranded repair molecules for different strategies described in this article for site-directed genomic alteration.
66. Biet E., Maurisse R., Dutreix M., Sun J.-S. Stimulation of Rec-A-mediated D-loop formation by oligonucleotide-directed triple-helix formation: guided homologous recombination (GOREC). Biochemistry. 40:2001;1779-1786.
67. Maurisse R., Feugeas J.-P., Biet E., Kuzniak I., Leboulch P., Dutreix M., Sun J.-S. A new method (GOREC) for directed mutagenesis and gene repair by homologous recombination. Gene Ther. 9:2002;703-707. If the high rates of gene conversion observed in this system can be replicated in vivo, this gene repair technology could have great potential.
68. Nishikawa M., Huang L. Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum Gene Ther. 12:2001;861-870. An excellent review on the current status of the nonviral delivery for gene therapy, emphasizing the barriers that have made this process less efficient than viral delivery methods.
69. Ferber D. Gene therapy: safer and virus free? Science. 294:2001;1638-1642. An insightful look at the current status of gene therapy.
70. Alexeev V, Igoucheva O, Yoon K: Simultaneous targeted alteration of the tyrosinase and c-kit genes by single-stranded oligonucleotides. Gene Ther: in press. The first report to demonstrate the feasibility of simultaneously targeting two genes in a single cell.
71. Pierce EA, Liu Q, Igoucheva O, Omarrudin R, Ma HC, Diamond S, Yoon K: Oligonucleotide-directed single-base DNA alterations in mouse embryonic stem cells. Gene Ther: in press. A seminal report demonstrating that SSONs can produce ES cells with precise mutations in any gene. The next step is to test whether SSONs can create accurate mouse models of inherited diseases by this relatively simple method.